Insulet Corporation (PODD) Discusses Recent Product Recalls and Physician Community Response at ADA Meeting Transcript

Insulet Corporation (PODD) Discusses Recent Product Recalls and Physician Community Response at ADA Meeting Transcript

Seeking Alpha • Jun 12, 2026

Why Insulet (PODD) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Jun 11, 2026

Insulet Corporation Valuation Pressure Has Dropped Enough (Upgrade)

Insulet Corporation has rebounded with strong revenue and profit growth, now approaching the lower end of fair value. PODD delivered Q1 2026 revenue of $761.7M (+33.9% YoY), with net income and operating cash flow nearly doubling. Management forecasts 21–23% revenue growth in 2026, driven by Omnipod 5 adoption and international expansion, despite competitive threats from weight-loss drugs.

Seeking Alpha • Jun 8, 2026

Why Is Insulet (PODD) Down 8.7% Since Last Earnings Report?

Insulet (PODD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 5, 2026

Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions

ACTON, Mass.--(BUSINESS WIRE)--Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at ADA.

Business Wire • Jun 4, 2026

Insulet Corporation (PODD) Presents at 46th Annual William Blair Growth Stock Conference Transcript

Insulet Corporation (PODD) Presents at 46th Annual William Blair Growth Stock Conference Transcript

Seeking Alpha • Jun 3, 2026

Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor

ACTON, Mass.--(BUSINESS WIRE)--Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor.

Business Wire • Jun 3, 2026

Insulet (PODD) is a Top-Ranked Growth Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Jun 2, 2026

US court overturns Insulet's $452 mln insulin-pump trade secret verdict against EOFlow

A U.S. ‌appeals court on Thursday overturned a $452 million verdict that ​medical device maker ​Insulet won against Korean rival ⁠EOFlow for allegedly ​stealing trade secrets related ​to its insulin-pump technology.

Reuters • May 28, 2026

PODD Stock: What a Hold Rating Says at a $163 Target

Insulet earns a short-term Hold as outlook rises; a $163 sales-based target tests whether growth can beat 2026 volatility.

Zacks Investment Research • May 28, 2026